Precision Targeting of Hepatic Stellate Cells: Nanotherapeutic Strategies for Liver Fibrosis Regression
WIREs Nanomedicine and Nanobiotechnology · 2026-01 · 18 (1)
DOI: 10.1002/wnan.70046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 02.01.2026. Verfasst von Xinying Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Nanomedicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: Department of Science and Technology of Liaoning Province.
Abstract (Originalsprache)
Liver fibrosis (LF), a major global health burden causing over two million deaths annually, arises from chronic injury leading to hepatic stellate cell (HSC) activation and pathological extracellular matrix (ECM) deposition. Current therapies are limited by nonspecific biodistribution and inadequate drug delivery to HSCs. Nanosystems engineered for active HSC targeting offer a promising approach to overcome fibrotic barriers—including capillarized sinusoids and dense ECM—through strategies such as receptor‐specific ligand modification, RNA‐based gene silencing, and multifunctional combinatorial therapies. These platforms enable precise modulation of HSC activation and ECM remodeling, promoting fibrosis regression while sparing healthy tissue. Despite promising preclinical outcomes, key challenges remain in biosafety, scalable fabrication, and clinical validation. Advancements in HSC‐specific nanotherapeutics hold transformative potential for reversing liver fibrosis and restoring hepatic function. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
ORCID-Profile: Ming Zhao, Haiyang Hu
Förderung
- Department of Science and Technology of Liaoning Province
Zitieren
APA
Ma, X., Chen, D., Zhao, M., & Hu, H. (2026). Precision Targeting of Hepatic Stellate Cells: Nanotherapeutic Strategies for Liver Fibrosis Regression. WIREs Nanomedicine and Nanobiotechnology, 18(1). https://doi.org/10.1002/wnan.70046
Vancouver
Ma X, Chen D, Zhao M, Hu H. Precision Targeting of Hepatic Stellate Cells: Nanotherapeutic Strategies for Liver Fibrosis Regression. WIREs Nanomedicine and Nanobiotechnology. 2026;18(1). doi:10.1002/wnan.70046
BibTeX
@article{Ma2026,
author = {Ma, Xinying and Chen, Dawei and Zhao, Ming and Hu, Haiyang},
title = {Precision Targeting of Hepatic Stellate Cells: Nanotherapeutic Strategies for Liver Fibrosis Regression},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2026},
volume = {18},
number = {1},
doi = {10.1002/wnan.70046}
}
EUVIMED